Money Matters - Simplified

Teva Pharmaceutical

CEL-SCI Investors Cheer a Bit Too Loudly


I don't usually write about the starts of clinical trials, and I've even been known to send snarky replies to PR people who pitch them to me via email. I mean, really, tell me when the thing ends; that's the data investors care about, since it drives the stock price.

Why the Street Should Love Teva Pharmaceutical's Earnings


Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company's economic output. That's because earnings are very often less trustworthy than cash flow, since earnings are more open to manipulation based on dubious judgment calls.

Teva Is Running Scared

 Chief medical Fool Brian Orelli thinks that newly approved multiple sclerosis drug Gilenya from Novartis (NYSE: NVS) might not grab much of the MS therapy market after all. But Teva Pharmaceutical (Nasdaq:TEVA), which makes established MS drug Copaxone, seems to be shaking in its boots.

 2010 UCLICK L.L.C.

Teva's New Drugs Pay Off

 For generic-drug companies, margins are ultimately everything. The business is built on volume and how efficiently a company can produce copycat drugs.

 

Today's Buy Opportunity: Teva Pharmaceutical

Welcome to "11 O'Clock Stock." Here at Fool.com, we'll be finding a new great stock at 11 a.m. ET every weekday for 50 days. Better yet, we're so confident in the picks that we're investing $50,000 of the Fool's own money in them! To hear more about the series, click here to see a video from Motley Fool co-founder Tom Gardner. Can't make it at 11 a.m. ET? Come back to Fool.com, and we'll have the article in our Top Stories section 24 hours a day.